nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—CYP1A2—Imiquimod—skin cancer	0.215	0.452	CbGbCtD
Pentoxifylline—CYP1A2—Vemurafenib—skin cancer	0.118	0.247	CbGbCtD
Pentoxifylline—CYP1A2—Dacarbazine—skin cancer	0.0903	0.19	CbGbCtD
Pentoxifylline—CYP1A2—Fluorouracil—skin cancer	0.0529	0.111	CbGbCtD
Pentoxifylline—PDE5A—penis—skin cancer	0.021	0.147	CbGeAlD
Pentoxifylline—ADORA1—nerve—skin cancer	0.00914	0.0639	CbGeAlD
Pentoxifylline—PDE5A—endothelium—skin cancer	0.00821	0.0574	CbGeAlD
Pentoxifylline—PDE5A—blood vessel—skin cancer	0.00757	0.0529	CbGeAlD
Pentoxifylline—ADORA2B—nipple—skin cancer	0.00723	0.0505	CbGeAlD
Pentoxifylline—NT5E—connective tissue—skin cancer	0.00598	0.0418	CbGeAlD
Pentoxifylline—NT5E—epithelium—skin cancer	0.00568	0.0397	CbGeAlD
Pentoxifylline—NT5E—skin of body—skin cancer	0.0054	0.0378	CbGeAlD
Pentoxifylline—NT5E—mammalian vulva—skin cancer	0.00493	0.0344	CbGeAlD
Pentoxifylline—NT5E—lymphoid tissue—skin cancer	0.00438	0.0306	CbGeAlD
Pentoxifylline—NT5E—female reproductive system—skin cancer	0.00422	0.0295	CbGeAlD
Pentoxifylline—ADORA2B—mammalian vulva—skin cancer	0.00422	0.0295	CbGeAlD
Pentoxifylline—PDE5A—connective tissue—skin cancer	0.00388	0.0271	CbGeAlD
Pentoxifylline—NT5E—Differentiation Pathway—SHH—skin cancer	0.00386	0.0682	CbGpPWpGaD
Pentoxifylline—PDE4B—nipple—skin cancer	0.00384	0.0268	CbGeAlD
Pentoxifylline—PDE5A—epithelium—skin cancer	0.00369	0.0258	CbGeAlD
Pentoxifylline—NT5E—head—skin cancer	0.00353	0.0246	CbGeAlD
Pentoxifylline—ADORA2A—lymphoid tissue—skin cancer	0.00312	0.0218	CbGeAlD
Pentoxifylline—ADORA2B—head—skin cancer	0.00302	0.0211	CbGeAlD
Pentoxifylline—ADORA2A—female reproductive system—skin cancer	0.00301	0.021	CbGeAlD
Pentoxifylline—PDE5A—female reproductive system—skin cancer	0.00274	0.0191	CbGeAlD
Pentoxifylline—ADORA1—female reproductive system—skin cancer	0.0026	0.0181	CbGeAlD
Pentoxifylline—ADORA2A—head—skin cancer	0.00251	0.0176	CbGeAlD
Pentoxifylline—NT5E—lymph node—skin cancer	0.00247	0.0173	CbGeAlD
Pentoxifylline—CYP1A2—nipple—skin cancer	0.00236	0.0165	CbGeAlD
Pentoxifylline—PDE5A—head—skin cancer	0.00229	0.016	CbGeAlD
Pentoxifylline—PDE4B—mammalian vulva—skin cancer	0.00224	0.0157	CbGeAlD
Pentoxifylline—ADORA1—head—skin cancer	0.00217	0.0152	CbGeAlD
Pentoxifylline—PDE4B—lymphoid tissue—skin cancer	0.00199	0.0139	CbGeAlD
Pentoxifylline—PDE4B—female reproductive system—skin cancer	0.00192	0.0134	CbGeAlD
Pentoxifylline—PDE4A—lymph node—skin cancer	0.00188	0.0132	CbGeAlD
Pentoxifylline—NT5E—HIF-1-alpha transcription factor network—TERT—skin cancer	0.00163	0.0288	CbGpPWpGaD
Pentoxifylline—PDE4B—head—skin cancer	0.0016	0.0112	CbGeAlD
Pentoxifylline—PDE5A—lymph node—skin cancer	0.0016	0.0112	CbGeAlD
Pentoxifylline—ADORA1—lymph node—skin cancer	0.00152	0.0106	CbGeAlD
Pentoxifylline—ADORA2B—G alpha (s) signalling events—MC1R—skin cancer	0.00128	0.0226	CbGpPWpGaD
Pentoxifylline—PDE4A—G alpha (s) signalling events—MC1R—skin cancer	0.00117	0.0206	CbGpPWpGaD
Pentoxifylline—PDE4B—lymph node—skin cancer	0.00112	0.00785	CbGeAlD
Pentoxifylline—PDE4B—G alpha (s) signalling events—MC1R—skin cancer	0.00108	0.019	CbGpPWpGaD
Pentoxifylline—Tachycardia—Imiquimod—skin cancer	0.00108	0.00332	CcSEcCtD
Pentoxifylline—Skin disorder—Imiquimod—skin cancer	0.00107	0.00331	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Imiquimod—skin cancer	0.00107	0.00329	CcSEcCtD
Pentoxifylline—Anorexia—Imiquimod—skin cancer	0.00105	0.00325	CcSEcCtD
Pentoxifylline—Angina pectoris—Fluorouracil—skin cancer	0.00104	0.00322	CcSEcCtD
Pentoxifylline—Infestation NOS—Temozolomide—skin cancer	0.00104	0.0032	CcSEcCtD
Pentoxifylline—Infestation—Temozolomide—skin cancer	0.00104	0.0032	CcSEcCtD
Pentoxifylline—Hepatitis—Dactinomycin—skin cancer	0.00103	0.00318	CcSEcCtD
Pentoxifylline—Flushing—Bleomycin—skin cancer	0.00103	0.00316	CcSEcCtD
Pentoxifylline—Body temperature increased—Vemurafenib—skin cancer	0.00102	0.00316	CcSEcCtD
Pentoxifylline—Pancytopenia—Fluorouracil—skin cancer	0.00102	0.00314	CcSEcCtD
Pentoxifylline—Swelling—Docetaxel—skin cancer	0.00102	0.00313	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00101	0.0031	CcSEcCtD
Pentoxifylline—Insomnia—Imiquimod—skin cancer	0.000999	0.00308	CcSEcCtD
Pentoxifylline—Dyspnoea—Imiquimod—skin cancer	0.000985	0.00304	CcSEcCtD
Pentoxifylline—Somnolence—Imiquimod—skin cancer	0.000982	0.00303	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Temozolomide—skin cancer	0.000982	0.00303	CcSEcCtD
Pentoxifylline—Dyspepsia—Imiquimod—skin cancer	0.000972	0.003	CcSEcCtD
Pentoxifylline—Erythema—Bleomycin—skin cancer	0.000962	0.00296	CcSEcCtD
Pentoxifylline—Decreased appetite—Imiquimod—skin cancer	0.00096	0.00296	CcSEcCtD
Pentoxifylline—Infestation NOS—Fluorouracil—skin cancer	0.000956	0.00295	CcSEcCtD
Pentoxifylline—Infestation—Fluorouracil—skin cancer	0.000956	0.00295	CcSEcCtD
Pentoxifylline—Flushing—Dactinomycin—skin cancer	0.000956	0.00295	CcSEcCtD
Pentoxifylline—Hypersensitivity—Vemurafenib—skin cancer	0.000954	0.00294	CcSEcCtD
Pentoxifylline—Haemoglobin—Temozolomide—skin cancer	0.000936	0.00289	CcSEcCtD
Pentoxifylline—Haemorrhage—Temozolomide—skin cancer	0.000932	0.00287	CcSEcCtD
Pentoxifylline—Hepatitis—Temozolomide—skin cancer	0.000932	0.00287	CcSEcCtD
Pentoxifylline—Conjunctivitis—Fluorouracil—skin cancer	0.00093	0.00287	CcSEcCtD
Pentoxifylline—Asthenia—Vemurafenib—skin cancer	0.000929	0.00287	CcSEcCtD
Pentoxifylline—Pruritus—Vemurafenib—skin cancer	0.000916	0.00283	CcSEcCtD
Pentoxifylline—ADORA1—Circadian rythm related genes—NKX2-1—skin cancer	0.000914	0.0161	CbGpPWpGaD
Pentoxifylline—Feeling abnormal—Imiquimod—skin cancer	0.00091	0.00281	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Imiquimod—skin cancer	0.000903	0.00279	CcSEcCtD
Pentoxifylline—Epistaxis—Fluorouracil—skin cancer	0.000902	0.00278	CcSEcCtD
Pentoxifylline—Erythema—Dactinomycin—skin cancer	0.000897	0.00277	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Bleomycin—skin cancer	0.000892	0.00275	CcSEcCtD
Pentoxifylline—Anaemia—Bleomycin—skin cancer	0.000889	0.00274	CcSEcCtD
Pentoxifylline—Diarrhoea—Vemurafenib—skin cancer	0.000886	0.00273	CcSEcCtD
Pentoxifylline—Urticaria—Imiquimod—skin cancer	0.000878	0.00271	CcSEcCtD
Pentoxifylline—Body temperature increased—Imiquimod—skin cancer	0.000873	0.00269	CcSEcCtD
Pentoxifylline—Abdominal pain—Imiquimod—skin cancer	0.000873	0.00269	CcSEcCtD
Pentoxifylline—Malaise—Bleomycin—skin cancer	0.000867	0.00267	CcSEcCtD
Pentoxifylline—Flushing—Temozolomide—skin cancer	0.000865	0.00267	CcSEcCtD
Pentoxifylline—Haemoglobin—Fluorouracil—skin cancer	0.000863	0.00266	CcSEcCtD
Pentoxifylline—Leukopenia—Bleomycin—skin cancer	0.000861	0.00265	CcSEcCtD
Pentoxifylline—Haemorrhage—Fluorouracil—skin cancer	0.000858	0.00265	CcSEcCtD
Pentoxifylline—Dizziness—Vemurafenib—skin cancer	0.000857	0.00264	CcSEcCtD
Pentoxifylline—ADORA2B—G alpha (s) signalling events—PTGER4—skin cancer	0.000844	0.0149	CbGpPWpGaD
Pentoxifylline—ADORA2A—G alpha (s) signalling events—MC1R—skin cancer	0.000843	0.0149	CbGpPWpGaD
Pentoxifylline—Immune system disorder—Temozolomide—skin cancer	0.000842	0.00259	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Dactinomycin—skin cancer	0.000832	0.00257	CcSEcCtD
Pentoxifylline—Anaemia—Dactinomycin—skin cancer	0.000829	0.00256	CcSEcCtD
Pentoxifylline—Vomiting—Vemurafenib—skin cancer	0.000824	0.00254	CcSEcCtD
Pentoxifylline—Chest pain—Bleomycin—skin cancer	0.000819	0.00252	CcSEcCtD
Pentoxifylline—Myalgia—Bleomycin—skin cancer	0.000819	0.00252	CcSEcCtD
Pentoxifylline—Rash—Vemurafenib—skin cancer	0.000817	0.00252	CcSEcCtD
Pentoxifylline—Dermatitis—Vemurafenib—skin cancer	0.000816	0.00252	CcSEcCtD
Pentoxifylline—Hypersensitivity—Imiquimod—skin cancer	0.000814	0.00251	CcSEcCtD
Pentoxifylline—Headache—Vemurafenib—skin cancer	0.000811	0.0025	CcSEcCtD
Pentoxifylline—Erythema—Temozolomide—skin cancer	0.000811	0.0025	CcSEcCtD
Pentoxifylline—Discomfort—Bleomycin—skin cancer	0.000809	0.00249	CcSEcCtD
Pentoxifylline—Malaise—Dactinomycin—skin cancer	0.000809	0.00249	CcSEcCtD
Pentoxifylline—Leukopenia—Dactinomycin—skin cancer	0.000803	0.00248	CcSEcCtD
Pentoxifylline—Dysgeusia—Temozolomide—skin cancer	0.000794	0.00245	CcSEcCtD
Pentoxifylline—Asthenia—Imiquimod—skin cancer	0.000793	0.00244	CcSEcCtD
Pentoxifylline—Confusional state—Bleomycin—skin cancer	0.000791	0.00244	CcSEcCtD
Pentoxifylline—Oedema—Bleomycin—skin cancer	0.000785	0.00242	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Bleomycin—skin cancer	0.000785	0.00242	CcSEcCtD
Pentoxifylline—Back pain—Temozolomide—skin cancer	0.000785	0.00242	CcSEcCtD
Pentoxifylline—Pruritus—Imiquimod—skin cancer	0.000782	0.00241	CcSEcCtD
Pentoxifylline—Infection—Bleomycin—skin cancer	0.00078	0.0024	CcSEcCtD
Pentoxifylline—Nausea—Vemurafenib—skin cancer	0.000769	0.00237	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Bleomycin—skin cancer	0.000768	0.00237	CcSEcCtD
Pentoxifylline—Arrhythmia—Fluorouracil—skin cancer	0.000767	0.00236	CcSEcCtD
Pentoxifylline—PDE4A—G alpha (s) signalling events—PTGER4—skin cancer	0.000766	0.0135	CbGpPWpGaD
Pentoxifylline—Vision blurred—Temozolomide—skin cancer	0.000764	0.00236	CcSEcCtD
Pentoxifylline—Myalgia—Dactinomycin—skin cancer	0.000763	0.00235	CcSEcCtD
Pentoxifylline—Bronchospasm—Docetaxel—skin cancer	0.000761	0.00235	CcSEcCtD
Pentoxifylline—Tremor—Temozolomide—skin cancer	0.00076	0.00234	CcSEcCtD
Pentoxifylline—Diarrhoea—Imiquimod—skin cancer	0.000756	0.00233	CcSEcCtD
Pentoxifylline—Discomfort—Dactinomycin—skin cancer	0.000754	0.00233	CcSEcCtD
Pentoxifylline—Angina pectoris—Docetaxel—skin cancer	0.000754	0.00233	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Temozolomide—skin cancer	0.000753	0.00232	CcSEcCtD
Pentoxifylline—Anaemia—Temozolomide—skin cancer	0.00075	0.00231	CcSEcCtD
Pentoxifylline—Anorexia—Bleomycin—skin cancer	0.000748	0.00231	CcSEcCtD
Pentoxifylline—Erythema—Fluorouracil—skin cancer	0.000747	0.0023	CcSEcCtD
Pentoxifylline—Agitation—Temozolomide—skin cancer	0.000745	0.0023	CcSEcCtD
Pentoxifylline—Angioedema—Temozolomide—skin cancer	0.000741	0.00229	CcSEcCtD
Pentoxifylline—Pancytopenia—Docetaxel—skin cancer	0.000735	0.00227	CcSEcCtD
Pentoxifylline—Hypotension—Bleomycin—skin cancer	0.000733	0.00226	CcSEcCtD
Pentoxifylline—NT5E—Differentiation Pathway—IL6—skin cancer	0.000733	0.0129	CbGpPWpGaD
Pentoxifylline—Oedema—Dactinomycin—skin cancer	0.000732	0.00226	CcSEcCtD
Pentoxifylline—Malaise—Temozolomide—skin cancer	0.000731	0.00226	CcSEcCtD
Pentoxifylline—Dizziness—Imiquimod—skin cancer	0.00073	0.00225	CcSEcCtD
Pentoxifylline—ADORA2A—GPCRs, Other—SMO—skin cancer	0.000729	0.0129	CbGpPWpGaD
Pentoxifylline—Infection—Dactinomycin—skin cancer	0.000727	0.00224	CcSEcCtD
Pentoxifylline—Leukopenia—Temozolomide—skin cancer	0.000726	0.00224	CcSEcCtD
Pentoxifylline—Palpitations—Temozolomide—skin cancer	0.000717	0.00221	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Dactinomycin—skin cancer	0.000717	0.00221	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000715	0.0022	CcSEcCtD
Pentoxifylline—ADORA2B—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000714	0.0126	CbGpPWpGaD
Pentoxifylline—PDE4B—G alpha (s) signalling events—PTGER4—skin cancer	0.000709	0.0125	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—NKX2-1—skin cancer	0.000706	0.0124	CbGpPWpGaD
Pentoxifylline—Vision blurred—Fluorouracil—skin cancer	0.000704	0.00217	CcSEcCtD
Pentoxifylline—Convulsion—Temozolomide—skin cancer	0.000703	0.00217	CcSEcCtD
Pentoxifylline—Vomiting—Imiquimod—skin cancer	0.000702	0.00217	CcSEcCtD
Pentoxifylline—Hypertension—Temozolomide—skin cancer	0.0007	0.00216	CcSEcCtD
Pentoxifylline—Dyspnoea—Bleomycin—skin cancer	0.0007	0.00216	CcSEcCtD
Pentoxifylline—Anorexia—Dactinomycin—skin cancer	0.000698	0.00215	CcSEcCtD
Pentoxifylline—Rash—Imiquimod—skin cancer	0.000696	0.00215	CcSEcCtD
Pentoxifylline—Dermatitis—Imiquimod—skin cancer	0.000696	0.00215	CcSEcCtD
Pentoxifylline—Headache—Imiquimod—skin cancer	0.000692	0.00213	CcSEcCtD
Pentoxifylline—Anaemia—Fluorouracil—skin cancer	0.000691	0.00213	CcSEcCtD
Pentoxifylline—Myalgia—Temozolomide—skin cancer	0.000691	0.00213	CcSEcCtD
Pentoxifylline—Infestation NOS—Docetaxel—skin cancer	0.00069	0.00213	CcSEcCtD
Pentoxifylline—Infestation—Docetaxel—skin cancer	0.00069	0.00213	CcSEcCtD
Pentoxifylline—Anxiety—Temozolomide—skin cancer	0.000688	0.00212	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000686	0.00211	CcSEcCtD
Pentoxifylline—Discomfort—Temozolomide—skin cancer	0.000682	0.0021	CcSEcCtD
Pentoxifylline—Decreased appetite—Bleomycin—skin cancer	0.000682	0.0021	CcSEcCtD
Pentoxifylline—Dry mouth—Temozolomide—skin cancer	0.000675	0.00208	CcSEcCtD
Pentoxifylline—Jaundice—Docetaxel—skin cancer	0.000673	0.00207	CcSEcCtD
Pentoxifylline—Conjunctivitis—Docetaxel—skin cancer	0.000671	0.00207	CcSEcCtD
Pentoxifylline—Leukopenia—Fluorouracil—skin cancer	0.000669	0.00206	CcSEcCtD
Pentoxifylline—Confusional state—Temozolomide—skin cancer	0.000667	0.00206	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000667	0.00206	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Temozolomide—skin cancer	0.000662	0.00204	CcSEcCtD
Pentoxifylline—Oedema—Temozolomide—skin cancer	0.000662	0.00204	CcSEcCtD
Pentoxifylline—Infection—Temozolomide—skin cancer	0.000658	0.00203	CcSEcCtD
Pentoxifylline—Nausea—Imiquimod—skin cancer	0.000656	0.00202	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Docetaxel—skin cancer	0.000653	0.00201	CcSEcCtD
Pentoxifylline—Epistaxis—Docetaxel—skin cancer	0.000651	0.00201	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Temozolomide—skin cancer	0.000648	0.002	CcSEcCtD
Pentoxifylline—Convulsion—Fluorouracil—skin cancer	0.000647	0.002	CcSEcCtD
Pentoxifylline—Feeling abnormal—Bleomycin—skin cancer	0.000647	0.00199	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR ligand binding—PTCH2—skin cancer	0.000644	0.0114	CbGpPWpGaD
Pentoxifylline—Skin disorder—Temozolomide—skin cancer	0.000643	0.00198	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Temozolomide—skin cancer	0.00064	0.00197	CcSEcCtD
Pentoxifylline—Myalgia—Fluorouracil—skin cancer	0.000636	0.00196	CcSEcCtD
Pentoxifylline—Chest pain—Fluorouracil—skin cancer	0.000636	0.00196	CcSEcCtD
Pentoxifylline—Decreased appetite—Dactinomycin—skin cancer	0.000636	0.00196	CcSEcCtD
Pentoxifylline—Anorexia—Temozolomide—skin cancer	0.000631	0.00195	CcSEcCtD
Pentoxifylline—Discomfort—Fluorouracil—skin cancer	0.000629	0.00194	CcSEcCtD
Pentoxifylline—Urticaria—Bleomycin—skin cancer	0.000623	0.00192	CcSEcCtD
Pentoxifylline—Haemoglobin—Docetaxel—skin cancer	0.000623	0.00192	CcSEcCtD
Pentoxifylline—Body temperature increased—Bleomycin—skin cancer	0.00062	0.00191	CcSEcCtD
Pentoxifylline—Haemorrhage—Docetaxel—skin cancer	0.00062	0.00191	CcSEcCtD
Pentoxifylline—Hepatitis—Docetaxel—skin cancer	0.00062	0.00191	CcSEcCtD
Pentoxifylline—Confusional state—Fluorouracil—skin cancer	0.000615	0.0019	CcSEcCtD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000612	0.0108	CbGpPWpGaD
Pentoxifylline—Oedema—Fluorouracil—skin cancer	0.00061	0.00188	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Fluorouracil—skin cancer	0.00061	0.00188	CcSEcCtD
Pentoxifylline—ADORA1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000607	0.0107	CbGpPWpGaD
Pentoxifylline—Infection—Fluorouracil—skin cancer	0.000606	0.00187	CcSEcCtD
Pentoxifylline—Feeling abnormal—Dactinomycin—skin cancer	0.000603	0.00186	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000603	0.00186	CcSEcCtD
Pentoxifylline—Insomnia—Temozolomide—skin cancer	0.000599	0.00185	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Dactinomycin—skin cancer	0.000598	0.00185	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Fluorouracil—skin cancer	0.000597	0.00184	CcSEcCtD
Pentoxifylline—Tachycardia—Fluorouracil—skin cancer	0.000595	0.00184	CcSEcCtD
Pentoxifylline—Dyspnoea—Temozolomide—skin cancer	0.00059	0.00182	CcSEcCtD
Pentoxifylline—Somnolence—Temozolomide—skin cancer	0.000588	0.00181	CcSEcCtD
Pentoxifylline—Dyspepsia—Temozolomide—skin cancer	0.000583	0.0018	CcSEcCtD
Pentoxifylline—Anorexia—Fluorouracil—skin cancer	0.000581	0.00179	CcSEcCtD
Pentoxifylline—Abdominal pain—Dactinomycin—skin cancer	0.000579	0.00178	CcSEcCtD
Pentoxifylline—Body temperature increased—Dactinomycin—skin cancer	0.000579	0.00178	CcSEcCtD
Pentoxifylline—Hypersensitivity—Bleomycin—skin cancer	0.000578	0.00178	CcSEcCtD
Pentoxifylline—Decreased appetite—Temozolomide—skin cancer	0.000575	0.00177	CcSEcCtD
Pentoxifylline—Flushing—Docetaxel—skin cancer	0.000575	0.00177	CcSEcCtD
Pentoxifylline—Hypotension—Fluorouracil—skin cancer	0.00057	0.00176	CcSEcCtD
Pentoxifylline—Constipation—Temozolomide—skin cancer	0.000566	0.00175	CcSEcCtD
Pentoxifylline—Asthenia—Bleomycin—skin cancer	0.000563	0.00174	CcSEcCtD
Pentoxifylline—Immune system disorder—Docetaxel—skin cancer	0.00056	0.00173	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000556	0.00171	CcSEcCtD
Pentoxifylline—Pruritus—Bleomycin—skin cancer	0.000555	0.00171	CcSEcCtD
Pentoxifylline—ADORA2A—G alpha (s) signalling events—PTGER4—skin cancer	0.000554	0.00977	CbGpPWpGaD
Pentoxifylline—Arrhythmia—Docetaxel—skin cancer	0.000554	0.00171	CcSEcCtD
Pentoxifylline—Insomnia—Fluorouracil—skin cancer	0.000552	0.0017	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—PTCH2—skin cancer	0.000548	0.00967	CbGpPWpGaD
Pentoxifylline—Feeling abnormal—Temozolomide—skin cancer	0.000545	0.00168	CcSEcCtD
Pentoxifylline—Dyspnoea—Fluorouracil—skin cancer	0.000544	0.00168	CcSEcCtD
Pentoxifylline—Somnolence—Fluorouracil—skin cancer	0.000542	0.00167	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Temozolomide—skin cancer	0.000541	0.00167	CcSEcCtD
Pentoxifylline—Erythema—Docetaxel—skin cancer	0.000539	0.00166	CcSEcCtD
Pentoxifylline—Hypersensitivity—Dactinomycin—skin cancer	0.000539	0.00166	CcSEcCtD
Pentoxifylline—Dyspepsia—Fluorouracil—skin cancer	0.000537	0.00166	CcSEcCtD
Pentoxifylline—Decreased appetite—Fluorouracil—skin cancer	0.00053	0.00163	CcSEcCtD
Pentoxifylline—Dysgeusia—Docetaxel—skin cancer	0.000528	0.00163	CcSEcCtD
Pentoxifylline—Urticaria—Temozolomide—skin cancer	0.000526	0.00162	CcSEcCtD
Pentoxifylline—Asthenia—Dactinomycin—skin cancer	0.000525	0.00162	CcSEcCtD
Pentoxifylline—Body temperature increased—Temozolomide—skin cancer	0.000523	0.00161	CcSEcCtD
Pentoxifylline—Abdominal pain—Temozolomide—skin cancer	0.000523	0.00161	CcSEcCtD
Pentoxifylline—Back pain—Docetaxel—skin cancer	0.000522	0.00161	CcSEcCtD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00052	0.00918	CbGpPWpGaD
Pentoxifylline—Muscle spasms—Docetaxel—skin cancer	0.000519	0.0016	CcSEcCtD
Pentoxifylline—Feeling abnormal—Fluorouracil—skin cancer	0.000503	0.00155	CcSEcCtD
Pentoxifylline—Diarrhoea—Dactinomycin—skin cancer	0.000501	0.00154	CcSEcCtD
Pentoxifylline—Vomiting—Bleomycin—skin cancer	0.000499	0.00154	CcSEcCtD
Pentoxifylline—Anaemia—Docetaxel—skin cancer	0.000499	0.00154	CcSEcCtD
Pentoxifylline—Rash—Bleomycin—skin cancer	0.000495	0.00153	CcSEcCtD
Pentoxifylline—Dermatitis—Bleomycin—skin cancer	0.000494	0.00152	CcSEcCtD
Pentoxifylline—Hypersensitivity—Temozolomide—skin cancer	0.000488	0.0015	CcSEcCtD
Pentoxifylline—Urticaria—Fluorouracil—skin cancer	0.000485	0.00149	CcSEcCtD
Pentoxifylline—Leukopenia—Docetaxel—skin cancer	0.000483	0.00149	CcSEcCtD
Pentoxifylline—Body temperature increased—Fluorouracil—skin cancer	0.000482	0.00149	CcSEcCtD
Pentoxifylline—Palpitations—Docetaxel—skin cancer	0.000477	0.00147	CcSEcCtD
Pentoxifylline—Asthenia—Temozolomide—skin cancer	0.000475	0.00146	CcSEcCtD
Pentoxifylline—ADORA2B—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00047	0.00828	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000469	0.00827	CbGpPWpGaD
Pentoxifylline—Pruritus—Temozolomide—skin cancer	0.000468	0.00144	CcSEcCtD
Pentoxifylline—Convulsion—Docetaxel—skin cancer	0.000467	0.00144	CcSEcCtD
Pentoxifylline—Nausea—Bleomycin—skin cancer	0.000466	0.00144	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR ligand binding—MC1R—skin cancer	0.000466	0.00822	CbGpPWpGaD
Pentoxifylline—Hypertension—Docetaxel—skin cancer	0.000466	0.00144	CcSEcCtD
Pentoxifylline—Vomiting—Dactinomycin—skin cancer	0.000465	0.00143	CcSEcCtD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—CDKN2A—skin cancer	0.000465	0.0082	CbGpPWpGaD
Pentoxifylline—Rash—Dactinomycin—skin cancer	0.000461	0.00142	CcSEcCtD
Pentoxifylline—Myalgia—Docetaxel—skin cancer	0.000459	0.00142	CcSEcCtD
Pentoxifylline—Chest pain—Docetaxel—skin cancer	0.000459	0.00142	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000456	0.00141	CcSEcCtD
Pentoxifylline—Diarrhoea—Temozolomide—skin cancer	0.000453	0.0014	CcSEcCtD
Pentoxifylline—Hypersensitivity—Fluorouracil—skin cancer	0.000449	0.00139	CcSEcCtD
Pentoxifylline—Dry mouth—Docetaxel—skin cancer	0.000449	0.00138	CcSEcCtD
Pentoxifylline—Confusional state—Docetaxel—skin cancer	0.000444	0.00137	CcSEcCtD
Pentoxifylline—Oedema—Docetaxel—skin cancer	0.00044	0.00136	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Docetaxel—skin cancer	0.00044	0.00136	CcSEcCtD
Pentoxifylline—Dizziness—Temozolomide—skin cancer	0.000438	0.00135	CcSEcCtD
Pentoxifylline—Infection—Docetaxel—skin cancer	0.000437	0.00135	CcSEcCtD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—PTGS2—skin cancer	0.000435	0.00767	CbGpPWpGaD
Pentoxifylline—Nausea—Dactinomycin—skin cancer	0.000435	0.00134	CcSEcCtD
Pentoxifylline—NT5E—Metabolism—PLIN2—skin cancer	0.000434	0.00766	CbGpPWpGaD
Pentoxifylline—Shock—Docetaxel—skin cancer	0.000433	0.00134	CcSEcCtD
Pentoxifylline—Pruritus—Fluorouracil—skin cancer	0.000432	0.00133	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Docetaxel—skin cancer	0.000431	0.00133	CcSEcCtD
Pentoxifylline—Tachycardia—Docetaxel—skin cancer	0.00043	0.00132	CcSEcCtD
Pentoxifylline—Skin disorder—Docetaxel—skin cancer	0.000428	0.00132	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR ligand binding—PTCH2—skin cancer	0.000423	0.00746	CbGpPWpGaD
Pentoxifylline—Vomiting—Temozolomide—skin cancer	0.000421	0.0013	CcSEcCtD
Pentoxifylline—Anorexia—Docetaxel—skin cancer	0.00042	0.00129	CcSEcCtD
Pentoxifylline—Rash—Temozolomide—skin cancer	0.000417	0.00129	CcSEcCtD
Pentoxifylline—Diarrhoea—Fluorouracil—skin cancer	0.000417	0.00129	CcSEcCtD
Pentoxifylline—Dermatitis—Temozolomide—skin cancer	0.000417	0.00129	CcSEcCtD
Pentoxifylline—Headache—Temozolomide—skin cancer	0.000415	0.00128	CcSEcCtD
Pentoxifylline—Hypotension—Docetaxel—skin cancer	0.000411	0.00127	CcSEcCtD
Pentoxifylline—Dizziness—Fluorouracil—skin cancer	0.000403	0.00124	CcSEcCtD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000402	0.0071	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000402	0.00708	CbGpPWpGaD
Pentoxifylline—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000401	0.00124	CcSEcCtD
Pentoxifylline—ADORA2B—Signaling Pathways—RHOU—skin cancer	0.0004	0.00706	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000399	0.00704	CbGpPWpGaD
Pentoxifylline—Insomnia—Docetaxel—skin cancer	0.000398	0.00123	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—MC1R—skin cancer	0.000396	0.00699	CbGpPWpGaD
Pentoxifylline—Nausea—Temozolomide—skin cancer	0.000393	0.00121	CcSEcCtD
Pentoxifylline—Dyspnoea—Docetaxel—skin cancer	0.000392	0.00121	CcSEcCtD
Pentoxifylline—Somnolence—Docetaxel—skin cancer	0.000391	0.00121	CcSEcCtD
Pentoxifylline—Vomiting—Fluorouracil—skin cancer	0.000388	0.0012	CcSEcCtD
Pentoxifylline—Dyspepsia—Docetaxel—skin cancer	0.000387	0.00119	CcSEcCtD
Pentoxifylline—Rash—Fluorouracil—skin cancer	0.000385	0.00119	CcSEcCtD
Pentoxifylline—Dermatitis—Fluorouracil—skin cancer	0.000384	0.00118	CcSEcCtD
Pentoxifylline—Decreased appetite—Docetaxel—skin cancer	0.000383	0.00118	CcSEcCtD
Pentoxifylline—Headache—Fluorouracil—skin cancer	0.000382	0.00118	CcSEcCtD
Pentoxifylline—Constipation—Docetaxel—skin cancer	0.000376	0.00116	CcSEcCtD
Pentoxifylline—PDE4A—Signaling Pathways—RHOU—skin cancer	0.000363	0.00641	CbGpPWpGaD
Pentoxifylline—Feeling abnormal—Docetaxel—skin cancer	0.000363	0.00112	CcSEcCtD
Pentoxifylline—Nausea—Fluorouracil—skin cancer	0.000362	0.00112	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Docetaxel—skin cancer	0.00036	0.00111	CcSEcCtD
Pentoxifylline—NT5E—Metabolism—CSPG4—skin cancer	0.00035	0.00618	CbGpPWpGaD
Pentoxifylline—Abdominal pain—Docetaxel—skin cancer	0.000348	0.00107	CcSEcCtD
Pentoxifylline—Body temperature increased—Docetaxel—skin cancer	0.000348	0.00107	CcSEcCtD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000342	0.00603	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—RHOU—skin cancer	0.00034	0.006	CbGpPWpGaD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—NRAS—skin cancer	0.000338	0.00597	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—RHOU—skin cancer	0.000336	0.00593	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—SHH—skin cancer	0.000332	0.00586	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—PTCH2—skin cancer	0.000331	0.00583	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—FOXO4—skin cancer	0.000326	0.00575	CbGpPWpGaD
Pentoxifylline—Hypersensitivity—Docetaxel—skin cancer	0.000324	0.001	CcSEcCtD
Pentoxifylline—Asthenia—Docetaxel—skin cancer	0.000316	0.000974	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR ligand binding—SMO—skin cancer	0.000315	0.00555	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—PTCH1—skin cancer	0.000315	0.00555	CbGpPWpGaD
Pentoxifylline—Pruritus—Docetaxel—skin cancer	0.000311	0.00096	CcSEcCtD
Pentoxifylline—ADORA2A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000308	0.00544	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—PTGER4—skin cancer	0.000306	0.0054	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—MC1R—skin cancer	0.000306	0.0054	CbGpPWpGaD
Pentoxifylline—Diarrhoea—Docetaxel—skin cancer	0.000301	0.000929	CcSEcCtD
Pentoxifylline—PDE4A—Signaling by GPCR—PTCH2—skin cancer	0.0003	0.0053	CbGpPWpGaD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—KRAS—skin cancer	0.000291	0.00514	CbGpPWpGaD
Pentoxifylline—Dizziness—Docetaxel—skin cancer	0.000291	0.000898	CcSEcCtD
Pentoxifylline—PDE4A—G Protein Signaling Pathways—NRAS—skin cancer	0.000283	0.005	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—SHH—skin cancer	0.000282	0.00498	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—PTCH2—skin cancer	0.000281	0.00496	CbGpPWpGaD
Pentoxifylline—Vomiting—Docetaxel—skin cancer	0.00028	0.000863	CcSEcCtD
Pentoxifylline—PDE4B—Signaling by GPCR—PTCH2—skin cancer	0.000278	0.0049	CbGpPWpGaD
Pentoxifylline—Rash—Docetaxel—skin cancer	0.000278	0.000856	CcSEcCtD
Pentoxifylline—Dermatitis—Docetaxel—skin cancer	0.000277	0.000855	CcSEcCtD
Pentoxifylline—Headache—Docetaxel—skin cancer	0.000276	0.00085	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—SMO—skin cancer	0.000268	0.00472	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—PTCH1—skin cancer	0.000268	0.00472	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000264	0.00466	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—MC1R—skin cancer	0.000263	0.00464	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—RHOU—skin cancer	0.000263	0.00463	CbGpPWpGaD
Pentoxifylline—PDE4B—G Protein Signaling Pathways—NRAS—skin cancer	0.000262	0.00462	CbGpPWpGaD
Pentoxifylline—Nausea—Docetaxel—skin cancer	0.000261	0.000806	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—PTGER4—skin cancer	0.000261	0.00459	CbGpPWpGaD
Pentoxifylline—ADORA1—Circadian rythm related genes—CDK4—skin cancer	0.000257	0.00454	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—FOXO4—skin cancer	0.000251	0.00442	CbGpPWpGaD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—HRAS—skin cancer	0.000248	0.00437	CbGpPWpGaD
Pentoxifylline—PDE4A—G Protein Signaling Pathways—KRAS—skin cancer	0.000244	0.0043	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—MC1R—skin cancer	0.000239	0.00422	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—MC1R—skin cancer	0.000239	0.00422	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—ENO2—skin cancer	0.000238	0.0042	CbGpPWpGaD
Pentoxifylline—PDE4B—G Protein Signaling Pathways—KRAS—skin cancer	0.000226	0.00398	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—MC1R—skin cancer	0.000224	0.00395	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—MC1R—skin cancer	0.000221	0.0039	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—SHH—skin cancer	0.000218	0.00384	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—PTCH2—skin cancer	0.000217	0.00383	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—MC1R—skin cancer	0.000217	0.00383	CbGpPWpGaD
Pentoxifylline—PDE4A—G Protein Signaling Pathways—HRAS—skin cancer	0.000207	0.00365	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—PTCH1—skin cancer	0.000207	0.00364	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—SMO—skin cancer	0.000207	0.00364	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—MC1R—skin cancer	0.000203	0.00359	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—PTGER4—skin cancer	0.000201	0.00355	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—MC1R—skin cancer	0.000201	0.00354	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—CDK4—skin cancer	0.000199	0.00351	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PTCH2—skin cancer	0.000195	0.00345	CbGpPWpGaD
Pentoxifylline—PDE4B—G Protein Signaling Pathways—HRAS—skin cancer	0.000192	0.00338	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PTCH2—skin cancer	0.000177	0.00313	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—PTGER4—skin cancer	0.000173	0.00305	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—MC1R—skin cancer	0.000173	0.00305	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	0.000172	0.00304	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—SHH—skin cancer	0.00017	0.00301	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PTCH2—skin cancer	0.000166	0.00293	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PTCH2—skin cancer	0.000164	0.0029	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—PTCH1—skin cancer	0.000162	0.00285	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—SMO—skin cancer	0.000162	0.00285	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—PTGER4—skin cancer	0.000157	0.00277	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—PTGER4—skin cancer	0.000157	0.00277	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—MC1R—skin cancer	0.000157	0.00277	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—SHH—skin cancer	0.000155	0.00273	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—GLI2—skin cancer	0.000148	0.00261	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—PTGER4—skin cancer	0.000147	0.0026	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—SMO—skin cancer	0.000147	0.00259	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—PTCH1—skin cancer	0.000147	0.00259	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—PTGER4—skin cancer	0.000145	0.00257	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—SHH—skin cancer	0.000145	0.00256	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—SHH—skin cancer	0.000143	0.00252	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—PTGER4—skin cancer	0.000143	0.00252	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MC1R—skin cancer	0.000141	0.00249	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—GLI1—skin cancer	0.000139	0.00246	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—ERCC2—skin cancer	0.000138	0.00244	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—PTCH1—skin cancer	0.000137	0.00242	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—SMO—skin cancer	0.000137	0.00242	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—PTCH1—skin cancer	0.000136	0.00239	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—SMO—skin cancer	0.000136	0.00239	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—GLI2—skin cancer	0.000134	0.00237	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—PTGER4—skin cancer	0.000134	0.00236	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—BRAF—skin cancer	0.000133	0.00234	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—PTGER4—skin cancer	0.000132	0.00233	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SUFU—skin cancer	0.000132	0.00233	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.000128	0.00226	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PTCH2—skin cancer	0.000128	0.00226	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MC1R—skin cancer	0.000128	0.00226	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—GLI1—skin cancer	0.000126	0.00223	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—GLI2—skin cancer	0.000126	0.00222	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—GLI2—skin cancer	0.000124	0.00219	CbGpPWpGaD
Pentoxifylline—PDE4B—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	0.000122	0.00215	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—NRAS—skin cancer	0.000121	0.00213	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MC1R—skin cancer	0.00012	0.00212	CbGpPWpGaD
Pentoxifylline—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	0.00012	0.00212	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SUFU—skin cancer	0.00012	0.00211	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MC1R—skin cancer	0.000119	0.00209	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—GLI1—skin cancer	0.000118	0.00209	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—GLI1—skin cancer	0.000117	0.00206	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—PTGER4—skin cancer	0.000114	0.002	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SUFU—skin cancer	0.000112	0.00198	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—SHH—skin cancer	0.000112	0.00197	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SUFU—skin cancer	0.000111	0.00196	CbGpPWpGaD
Pentoxifylline—ADORA1—Circadian rythm related genes—TP53—skin cancer	0.00011	0.00193	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	0.000108	0.00191	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—SMO—skin cancer	0.000106	0.00187	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—PTCH1—skin cancer	0.000106	0.00187	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—KRAS—skin cancer	0.000104	0.00183	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—PTGER4—skin cancer	0.000103	0.00182	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SHH—skin cancer	0.000101	0.00178	CbGpPWpGaD
Pentoxifylline—ADORA1—Circadian rythm related genes—IL6—skin cancer	0.0001	0.00177	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—RASA1—skin cancer	0.0001	0.00176	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	9.98e-05	0.00176	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—GLI2—skin cancer	9.72e-05	0.00171	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PTCH1—skin cancer	9.54e-05	0.00168	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SMO—skin cancer	9.54e-05	0.00168	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	9.33e-05	0.00165	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PTGER4—skin cancer	9.29e-05	0.00164	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MC1R—skin cancer	9.27e-05	0.00164	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—TP53—skin cancer	9.22e-05	0.00163	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SHH—skin cancer	9.14e-05	0.00161	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—GLI1—skin cancer	9.14e-05	0.00161	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—RASA1—skin cancer	9.08e-05	0.0016	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	8.99e-05	0.00159	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—HRAS—skin cancer	8.82e-05	0.00156	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SUFU—skin cancer	8.66e-05	0.00153	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PTCH1—skin cancer	8.66e-05	0.00153	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SMO—skin cancer	8.66e-05	0.00153	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	8.59e-05	0.00152	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SHH—skin cancer	8.56e-05	0.00151	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—RASA1—skin cancer	8.5e-05	0.0015	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SHH—skin cancer	8.46e-05	0.00149	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—TP53—skin cancer	8.46e-05	0.00149	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PTGER4—skin cancer	8.43e-05	0.00149	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—RASA1—skin cancer	8.4e-05	0.00148	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—NRAS—skin cancer	8.34e-05	0.00147	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—PTGS2—skin cancer	8.29e-05	0.00146	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—FOXO4—skin cancer	8.2e-05	0.00145	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SMO—skin cancer	8.11e-05	0.00143	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PTCH1—skin cancer	8.11e-05	0.00143	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PTCH1—skin cancer	8.02e-05	0.00141	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SMO—skin cancer	8.02e-05	0.00141	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	7.93e-05	0.0014	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PTGER4—skin cancer	7.9e-05	0.00139	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PTGER4—skin cancer	7.8e-05	0.00138	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—IL6—skin cancer	7.74e-05	0.00137	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	7.59e-05	0.00134	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—FOXO4—skin cancer	7.45e-05	0.00131	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	7.3e-05	0.00129	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—KRAS—skin cancer	7.18e-05	0.00127	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—FOXO4—skin cancer	6.98e-05	0.00123	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—FOXO4—skin cancer	6.89e-05	0.00122	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SHH—skin cancer	6.61e-05	0.00117	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—RASA1—skin cancer	6.57e-05	0.00116	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PTCH1—skin cancer	6.26e-05	0.0011	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SMO—skin cancer	6.26e-05	0.0011	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—HRAS—skin cancer	6.1e-05	0.00108	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PTGER4—skin cancer	6.1e-05	0.00108	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—IL6—skin cancer	5.84e-05	0.00103	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TERT—skin cancer	5.48e-05	0.000967	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—FOXO4—skin cancer	5.39e-05	0.00095	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TERT—skin cancer	4.98e-05	0.000878	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TERT—skin cancer	4.66e-05	0.000822	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—NRAS—skin cancer	4.62e-05	0.000814	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TERT—skin cancer	4.6e-05	0.000812	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—BRAF—skin cancer	4.34e-05	0.000765	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—NRAS—skin cancer	4.19e-05	0.000739	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PLIN2—skin cancer	4e-05	0.000706	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—KRAS—skin cancer	3.97e-05	0.000701	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—BRAF—skin cancer	3.94e-05	0.000695	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—NRAS—skin cancer	3.93e-05	0.000692	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—NRAS—skin cancer	3.88e-05	0.000684	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—BRAF—skin cancer	3.69e-05	0.000651	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—BRAF—skin cancer	3.65e-05	0.000643	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—KRAS—skin cancer	3.61e-05	0.000636	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TERT—skin cancer	3.6e-05	0.000635	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—KRAS—skin cancer	3.38e-05	0.000596	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—HRAS—skin cancer	3.38e-05	0.000596	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—KRAS—skin cancer	3.34e-05	0.000589	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL6—skin cancer	3.23e-05	0.00057	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CSPG4—skin cancer	3.23e-05	0.000569	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—HRAS—skin cancer	3.07e-05	0.000541	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—NRAS—skin cancer	3.03e-05	0.000535	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL6—skin cancer	2.94e-05	0.000518	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—HRAS—skin cancer	2.87e-05	0.000507	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—BRAF—skin cancer	2.85e-05	0.000503	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—HRAS—skin cancer	2.84e-05	0.000501	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL6—skin cancer	2.75e-05	0.000485	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NRAS—skin cancer	2.73e-05	0.000481	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL6—skin cancer	2.72e-05	0.000479	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—KRAS—skin cancer	2.61e-05	0.00046	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NRAS—skin cancer	2.48e-05	0.000437	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—KRAS—skin cancer	2.35e-05	0.000414	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NRAS—skin cancer	2.32e-05	0.000409	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NRAS—skin cancer	2.29e-05	0.000404	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—HRAS—skin cancer	2.22e-05	0.000391	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ENO2—skin cancer	2.19e-05	0.000387	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—KRAS—skin cancer	2.13e-05	0.000376	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL6—skin cancer	2.12e-05	0.000374	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TP53—skin cancer	2.09e-05	0.000368	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—KRAS—skin cancer	2e-05	0.000352	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—HRAS—skin cancer	2e-05	0.000352	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—KRAS—skin cancer	1.97e-05	0.000348	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL6—skin cancer	1.91e-05	0.000337	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TP53—skin cancer	1.89e-05	0.000334	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—HRAS—skin cancer	1.81e-05	0.00032	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NRAS—skin cancer	1.79e-05	0.000316	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TP53—skin cancer	1.77e-05	0.000313	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TP53—skin cancer	1.75e-05	0.000309	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL6—skin cancer	1.73e-05	0.000306	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.72e-05	0.000303	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—HRAS—skin cancer	1.7e-05	0.000299	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—HRAS—skin cancer	1.68e-05	0.000296	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL6—skin cancer	1.62e-05	0.000286	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL6—skin cancer	1.6e-05	0.000283	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KRAS—skin cancer	1.54e-05	0.000272	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TP53—skin cancer	1.37e-05	0.000242	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—HRAS—skin cancer	1.31e-05	0.000231	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ERCC2—skin cancer	1.27e-05	0.000225	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL6—skin cancer	1.25e-05	0.000221	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTGS2—skin cancer	7.64e-06	0.000135	CbGpPWpGaD
